The life and times of a GSK patent
Carl Battle has a big job on his hands managing pharmaceutical giant GlaxoSmithKline’s patent team. Michael Loney talks to him and some of his staff about bringing Anoro Ellipta to market, the dreaded patent cliff, combating generic drug companies and navigating developing countries’ IP hostility
GlaxoSmithKline (GSK) received an early Christmas present in
December last year: the US Food and Drug Administration
approved its new treatment for patients with chronic
obstructive pulmonary disease (COPD). GSK has high hopes for
Anoro Ellipta, a product that Thomson...
Please
log in to read the rest of this article.
New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Already registered?
Please make sure you log in to read the rest of the article.
Log in
Join us now
Gain FREE access to up to five free articles when you register now. Join here